We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

The Breez 2 mL micro-bioreactor platform is a fully automated, functionally closed, and continuous perfusion cell culture ...

Celonic Group, a Swiss-Based Quality CDMO, is integrating Merck’s Breez micro-bioreactor platform into its process ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Investors can also look forward to a potential final approval by the Food and Drug Administration (FDA) for Merck's Clesrovimab monoclonal antibody addressing the large pediatric need to treat ...

Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK may work for income investors.

Merck booked just under $600 million last year ... Also in the cardiovascular pipeline is anti-factor IX antibody MK-2060, billed as a potentially safer anticoagulant that is being developed ...